Targeted manipulation of apoptosis in cancer treatment
Authors:
- S Gail EckhardtSES Gail Eckhardt
- D Ross CamidgeDCD Ross Camidge
- 1 October 2008
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (10) , 1002-1011
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the familyEMBO Reports, 2006
- Investigations on gossypol: past and present developmentsExpert Opinion on Investigational Drugs, 2005
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- The role of apoptosis in cancer development and treatment responseNature Reviews Cancer, 2005
- Intrinsic tumour suppressionNature, 2004
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999